立体定向体部放疗用于复发非小细胞肺癌的挽救治疗
本回顾性分析纳入40例接受胸部SBRT的复发NSCLC患者(共52次治疗),既往接受过EBRT、SBRT或手术切除。SBRT中位剂量40 Gy/4次,中位BED 79.60 Gy;局部控制率65%,中位总生存24.46个月,无≥3级毒性。既往SBRT者局部控制更优,BED≥80 Gy与更好局部无进展生存相关。
要点
- 复发NSCLC的SBRT挽救治疗局部控制率65%,中位总生存24.46个月
- 既往接受SBRT者局部控制87%,优于手术后33%
- BED≥80 Gy与改善的局部无进展生存和PFS相关
核心结论
- SBRT挽救治疗复发NSCLC有效且耐受良好,尤其对既往SBRT后复发者。
- 条件允许时,挽救SBRT应追求BED≥80 Gy。
研究设计与样本
- 回顾性分析纳入40例有既往EBRT、SBRT或手术切除史的胸部SBRT治疗患者,共52次治疗。
- 既往治疗包括EBRT 21次、SBRT 15次、手术切除9次及EBRT后SBRT 7次。
- 随访以每2–3个月PET和CT成像进行,采用Kaplan-Meier法分析结局。
主要发现
- SBRT中位剂量40 Gy/4次,中位BED 79.60 Gy,中位GTV 10.80 cm³,中位PTV 26.25 cm³。
- 局部控制率65%,中位局部失败时间13.52个月;既往SBRT后局部控制87%,手术后仅33%。
- 中位总生存24.46个月,中位无进展生存14.11个月。
- 既往SBRT者局部控制改善(P = .021),含EBRT后SBRT者亦改善(P = .0037);手术后局部控制趋势更差(P = .061)。
- BED≥80 Gy与局部无进展生存(P = .032)、PFS(P = .021)、无治疗失败时间(P = .033)及局部失败时间(P = .041)改善相关;Kaplan-Meier法示BED≥80 Gy预测局部PFS(P = .01)和PFS(P < .005)改善。
关键数值与推荐
- SBRT中位剂量40 Gy/4次,中位BED 79.60 Gy。
- BED≥80 Gy与局部PFS(P = .01)和PFS(P < .005)改善相关。
- 既往SBRT者局部控制87%,手术后33%。
临床怎么用
- 对复发NSCLC可考虑SBRT挽救治疗,尤其既往接受过SBRT者。
- 计划时应尽可能使BED达到≥80 Gy以改善局部控制。
- 既往手术切除后复发者挽救SBRT局部控制可能较差,需谨慎评估。
局限性
- 回顾性分析,样本量较小(40例、52次治疗)。
- 随访时间有限,中位影像随访13.39个月、临床随访19.01个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study analyzes the outcomes and toxicity of stereotactic body radiation therapy (SBRT) as salvage treatment for recurrent non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This retrospective analysis considered patients treated with thoracic SBRT and a history of prior external beam radiation therapy (EBRT), SBRT, or surgical resection for NSCLC. Follow-up included positron emission tomography and computed tomography imaging at 2- to 3-month intervals. Key outcomes were presented with the Kaplan-Meier method. RESULTS: Forty patients with 52 treatments were included at a mean of 11.82 months after treatment with EBRT (n = 21), SBRT (n = 15), surgical resection (n = 9), and SBRT after EBRT (n = 7). Median imaging and clinical follow-up were 13.39 and 19.01 months, respectively. SBRT delivered a median dose of 40 Gy in 4 fractions. Median biologically effective dose (BED) was 79.60 Gy. Median gross tumor volume and planning target volume were 10.80 and 26.25 cm3, respectively. Local control was 65%, with a median time to local failure of 13.52 months. Local control was 87% after previous SBRT but only 33% after surgery. Median overall survival was 24.46 months, and median progression-free survival (PFS) was 14.11 months. Patients presenting after previous SBRT had improved local control (P = .021), and the same result was obtained including patients with SBRT after EBRT (P = .0037). Treatments after surgical resection trended toward worse local control (P = .061). Patients with BED ≥80 Gy had improved local PFS (P = .032), PFS (P = .021), time without any treatment failure (P = .033), and time to local failure (P = .041). Using the Kaplan-Meier method, BED ≥80 Gy was predictive of improved local PFS (P = .01) and PFS (P < .005). Toxicity consisted of 10 instances of grade <3 toxicity (16%) and no grade ≥3 toxicity. CONCLUSIONS: Salvage treatment for recurrent NSCLC with SBRT was effective and well tolerated, particularly after initial treatment with SBRT. When possible, salvage SBRT should aim to achieve a BED of ≥80 Gy.
引用
- Kowalchuk RO, Waters MR, Richardson KM, et al. Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2020. PMID: 32454175. doi:10.1016/j.prro.2020.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。